Convincing FDA Medical Reviewers to Lift a Clinical Hold on Gene Therapy Trials
When the FDA places a clinical trial on hold following a Serious Adverse Event (SAE), getting the trial resumed requires presenting immutable vector biodistribution toxicology.
Vishal VermaCTO & Co-Founder, Dehurdle
March 22, 20234 min read
The Clinical Hold Resolution Presentation
Recommended Spoken Script
"Our preclinical toxicology reassessment proves the immune response was triggered by viral capsid antibody cross-reactivity at the highest dose tier. We have amended our investigational protocol to include mandatory baseline antibody screening and a 50% dose reduction, establishing a proven safety margin for trial resumption."
The 2-Minute Practice Drill
2-Minute Spoken Drill
The 2-Minute Practice Drill
Practice FDA clinical hold discussions in Dehurdle.